International Formulation Revenue Growth
₹2,147M
+94.6% YoY
International formulations grew 94.6% YoY to ₹2,147 million, driven by strong performance across regulated and emerging markets.
INDOCOREMEDIES
Other
15 May 2026
Indoco Remedies Limited — Q4 FY26
Indoco Remedies reported a strong Q4 FY26 with consolidated revenue of ₹456 crore, up 18.8% YoY, driven by a 94.6% surge in international formulations, particularly in regulated markets (US +77.5%, Europe +68.7%) and emerging markets (+134%).
✓ Verified against BSE filing
2-Min Summary
✦ AI-Generated from Full Transcript
Indoco Remedies reported a strong Q4 FY26 with consolidated revenue of ₹456 crore, up 18.8% YoY, driven by a 94.6% surge in international formulations, particularly in regulated markets (US +77.5%, Europe +68.7%) and emerging markets (+134%). Domestic formulation revenue declined 6% due to muted seasonal demand for anti-infectives and respiratory products, though prescription growth remained healthy. EBITDA margin improved to 10.9% (vs -0.2% last year) on operating leverage. Management guided for continued international momentum, with US liquid oral approvals and European contract manufacturing scaling up. Key risks include elevated debt (₹960 crore consolidated), stretched receivables from export growth, and the unresolved sterile plant issue limiting future US approvals.
Key Numbers
US Business Revenue
₹546M
+77.5% YoY
US business grew 77.5% YoY to ₹546 million, aided by solid oral sales and second-site transfers for sterile products.
Emerging Markets Revenue
₹746M
+134% YoY
Emerging markets revenue surged 134% YoY to ₹746 million, led by field force expansion in East and West Africa.
Debt Repayment Commitment
₹140Cr
per year for next 3 years
Management committed to repaying ~₹140 crore annually over the next three years, targeting debt reduction.
Management Guidance
Debt repayment of ~₹140 crore per year
Management committed to repaying approximately ₹140 crore each year for the next three years, with potential prepayment.
Management guidance otherNo major capex planned for next two years
Management stated no major capital expenditure is planned for the next two years, focusing on cash flow improvement.
Management guidance capexInternational business growth to continue
Management expects continued traction in international markets, with US liquid oral launches and European contract manufacturing scaling up.
Management guidance growthWarren Remedies API turnaround in 1-2 quarters
Management expects Warren Remedies' API business to improve once regulatory approvals and validations are completed, likely in a couple of quarters.
Management guidance otherKey Risks
High debt and stretched receivables
Consolidated debt stands at ~₹960 crore, with receivables growing 45% YoY due to longer credit periods in emerging markets, straining cash flow.
high · analyst_questionUnresolved sterile plant issue
The sterile plant at Pataganda remains unresolved, limiting future US approvals and requiring ongoing investment without immediate returns.
high · management_commentaryExchange rate volatility on ECB loan
A €10 million ECB loan caused a ₹24 crore exchange loss in Q4, impacting finance costs; further currency fluctuations could hurt profitability.
medium · analyst_questionDomestic business seasonality risk
Domestic formulation revenue declined 6% YoY due to weak seasonal demand for anti-infectives and respiratory products, with recovery uncertain.
medium · data_observationNotable Quotes
It gives me great joy to announce that after almost six quarters we are in positive in this quarter for performance.
We have a decent order book right now and I'm sure our team will work very hard to continue this kind of performance.
We do have a very impressive basket and a portfolio and we are mainly operating in eastern Africa... the confidence level is pretty high for next two to three years on this business.
Frequently Asked Questions
What was Indoco Remedies's revenue in Q4 FY26?
Indoco Remedies reported revenue of ₹476 Cr in Q4 FY26, representing a +18.8% change compared to the same quarter last year.
What guidance did Indoco Remedies management give for FY27?
Debt repayment of ~₹140 crore per year: Management committed to repaying approximately ₹140 crore each year for the next three years, with potential prepayment. No major capex planned for next two years: Management stated no major capital expenditure is planned for the next two years, focusing on cash flow improvement. International business growth to continue: Management expects continued traction in international markets, with US liquid oral launches and European contract manufacturing scaling up. Warren Remedies API turnaround in 1-2 quarters: Management expects Warren Remedies' API business to improve once regulatory approvals and validations are completed, likely in a couple of quarters.
What are the key risks for Indoco Remedies in FY27?
Key risks include High debt and stretched receivables — Consolidated debt stands at ~₹960 crore, with receivables growing 45% YoY due to longer credit periods in emerging markets, straining cash flow.; Unresolved sterile plant issue — The sterile plant at Pataganda remains unresolved, limiting future US approvals and requiring ongoing investment without immediate returns.; Exchange rate volatility on ECB loan — A €10 million ECB loan caused a ₹24 crore exchange loss in Q4, impacting finance costs; further currency fluctuations could hurt profitability.; Domestic business seasonality risk — Domestic formulation revenue declined 6% YoY due to weak seasonal demand for anti-infectives and respiratory products, with recovery uncertain..
Did Indoco Remedies meet its previous quarter's guidance?
Scorecard data is being built as historical quarters are processed.
Where can I read the full Indoco Remedies Q4 FY26 concall transcript?
The full earnings conference call transcript or source release is available on the linked source material. This page provides an AI-generated summary verified against official BSE/NSE filings.